- Eli Lilly's eczema drug Ebglyss received a positive recommendation from Canada's Drug Agency, supporting future public reimbursement.
- The company agreed a new distribution arrangement for cancer drug Verzenios in mainland China.
- The European Medicines Agency issued a positive opinion for Jaypirca in chronic lymphocytic leukemia, moving it closer to wider use in Europe.
Eli Lilly, ticker NYSE:LLY, is drawing fresh attention for developments outside its high profile obesity and diabetes portfolio. The stock trades at $1,216.95, with a 1 year return of 55.0% and a 5 year gain of about 4.5x, which shows how closely investors are watching additional avenues for the business. These new regulatory and commercial steps in dermatology and oncology sit alongside that recent share price performance.
For you as an investor, the key question is how far treatments like Ebglyss, Verzenios and Jaypirca can broaden Eli Lilly's mix of revenue over time. The latest moves in Canada, China and Europe indicate that management is continuing to build out immunology and cancer franchises beyond existing metabolic drugs, giving you more to track across different regions and therapy areas.
Stay updated on the most important news stories for Eli Lilly by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Eli Lilly.
3 things going right for Eli Lilly that this headline doesn't cover.
Investor Checklist: What This Means For Eli Lilly Stock
Quick Assessment
- ⚖️ Price vs Analyst Target: Eli Lilly trades at US$1,216.95 versus a consensus target of US$1,240.46, a gap of about 2%.
- ✅ Simply Wall St Valuation: The stock is flagged as trading roughly 23.5% below an estimated fair value.
- ✅ Recent Momentum: The 30 day return of 6.3% shows recent positive price momentum as these approvals progress.
There's only one way to know the right time to buy, sell or hold Eli Lilly. Head to Simply Wall St's company report for the latest analysis of Eli Lilly's Fair Value.
Key Considerations
- 📊 Ebglyss in Canada, Verzenios in China and Jaypirca in Europe collectively point to Eli Lilly expanding outside obesity and diabetes. This could influence how diversified future revenue becomes.
- 📊 Watch how quickly these treatments convert into funded access and prescribing uptake. It may also be useful to monitor any updates to analyst price targets around the current US$1,240.46 level.
- ⚠️ The company carries a high level of debt, so funding global launches and oncology expansion while managing the balance sheet remains an important risk to track.
Dig Deeper
For the full picture including more risks and rewards, check out the complete Eli Lilly analysis. Alternatively, you can check out the community page for Eli Lilly to see how other investors believe this latest news will impact the company's narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com